Pizza Pizza Royalty's high-margin, asset-light business model help sustain its increasing royalty pool and dividends. See ...

We believe Adobe (ADBE) stock may represent a good value buy. It is presently trading at a lower than average valuation, ...

In the heart of Overland Park sits a retail phenomenon that has Kansans setting their alarms, plotting road trips, and clearing trunk space with religious devotion. Ollie’s Bargain Outlet stands like ...

Domino's valuation has become more attractive.

Nvidia, led by CEO Jensen Huang, has seen its stock climb about 26% so far this year. With a quick look at conventional metrics, Nvidia's stock might not entirely scream "cheap." But the stock is ...

XOMA Royalty Corporation (NASDAQ: XOMA) stock plunged on Thursday after its partner Rezolute Inc. (NASDAQ: RZLT) reported disappointing trial results for its partnered product, Ersodetug (RZ358). The ...

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. AbbVie is also an excellent dividend stock. 10 stocks we like better than ...

Concerns about Nvidia have dragged the stock’s valuation near historically low levels — and that suggests big gains could be in store, according to a BofA analyst. Shares of the chip maker NVDA are ...

Strategy prides itself on being the largest corporate holder of Bitcoins. That strategy, however, is now working against the stock. It has oftentimes been a more volatile holding than Bitcoin itself.

Salesforce Inc. shares have never been cheaper, but investors still aren’t buying amid rising fears about artificial intelligence eroding the company’s growth prospects. The maker of customer ...

If you shudder at the price of groceries lately, you're not alone. Food has gotten prohibitively expensive for many Americans. Cheap, processed calorie-dense foods may seem appealing, but the toll ...

For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.